Search academic texts

Information × Registration Number 0219U102175, 0115U002970 , R & D reports Title Experimental justification of CD150 isoforms application as potential diagnostic markers and targets for directed anti-tumor therapy popup.stage_title Head Sidorenko Svitlana P., Доктор біологічних наук Registration Date 20-12-2019 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine popup.description2  The experimental model cell system with the knockout of the SLAMF1 gene - U87_CD150KO was created on the basis of U87 cells using the CRISPR / Cas9 system. of U87 cells express CD150 only in the cytoplasm of cells. Editing of the U87 cells genome by CRISPR / Cas9 resulted in loss of CD150 expression of U87_CD150KO cells, but did not affect the level of spontaneous apoptosis and cell viability. For the first time, the proliferative activity of U87 cells with the SLAMF1 knockout is shown to be lower than that of the U87 cells. For the first time, a difference in the sensitivity of U87 cells to the action of chemotherapeutic agents of different mechanism of action depending on SLAMF1 expression was established. U87 cells that are positive for both protein and RNA CD150 expression levels are more sensitive to temozolomide, a first-line treatment for glioblastoma patients, than U87 cells with negative SLAMF1 expression status. Knockout of SLAMF1 in U87 cells increases their sensitivity to both cisplatin and doxorubicin. The results of the studies are an experimental basis for the need to screen for CD150 expression in tumors of different histogenesis as a component that determines the individual biological properties of cells. Product Description popup.authors Hordiienko Inna M. Kovalevska Larysa M. Sidorenko Svitlana P. Shlapatska Larysa M. Scherbina Valeriia M. popup.nrat_date 2020-04-02 Close